Log In
BCIQ
Print this Print this
 

REGN2810, SAR439684

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
DescriptionHuman mAb against PD-1
Molecular Target Programmed cell death 1 (PD-1) (PDCD1) (CD279)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,665.0M

$640.0M

$375.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/28/2015

$2,665.0M

$640.0M

$375.0M

Get a free BioCentury trial today